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ABSTRACT 
Introduction: Iron deficiency (ID), measured as serum ferritin (SF), has been found in 
31% and 57% of elite male and female athletes respectively. In distance runners, ID has been 
found to affect up to 41% of men and 82% of women. There are significant health consequences 
of ID such as decreased bone mineral density, altered thyroid function, immune suppression, and 
fatigue. Purpose: To determine if there is a relationship between ID and training reductions due 
to injury, illness, and fatigue in collegiate distance runners. Hypothesis: Because ID affects bone 
health, fatigue, thyroid, and immune function, it is hypothesized that distance runners with ID 
experience training reductions more frequently than athletes with normal SF levels. Methods: A 
preexisting data set consisting 47 NCAA Division 1 cross country runners’ (M=20 years ± 1.69) 
SF, injury information, fatigue reports, and training volume was analyzed. SF levels were 
measured preceding the cross-country season in early September and following the season in 
early December. Athletes supplemented with ferrous sulfate elixir according to the SF level 
throughout the season. A generalized linear model investigated associations between training 
reduction, SF, and training volume. A chi-squared test compared ID athletes (≤35 μg/L) and 
athletes with normal SF (>35 μg/L). Significance was set at ≤ 0.05. Results: 57.4% of the athletes 
were IDNA at some point during the season. The IDNA group was twice as likely to experience a 
training reduction as the normal iron group (p < 0.05). Pre SF (B = -0.042 ± 0.0212), Post SF (B 
= 0.033 ± 0.0169), and training volume (B = -0.057 ± 0.0229) significantly predicted training 
reductions (p ≤ 0.05). Conclusion: IDNA was found to be associated with training reductions. 
Additionally, a higher pre SF value was associated with less training reduction. Athletes’ SF 
should be tested and corrected through supplementation and diet. 
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CHAPTER ONE: INTRODUCTION 
Iron deficiency (ID) has been a popular subject of study, with respect to health 
outcomes, due to its high prevalence among the general population, as well as its role in 
oxygen delivery, bone density, immune regulation and thyroid regulation.1-4 Athletes are 
at an increased risk for ID, particularly female distance runners, which has been found to 
be as high as 82%.5 Trained distance runners are also at an increased risk of injury, 
between 31% and 57%.6-8 The purpose of this study was to investigate the effect of ID on 
the training reductions caused by injury, illness, and fatigue of college distance runners. 
Iron Deficiency 
Iron deficiency (ID) is the lack of adequate iron to produce hemoglobin (Hb) for 
red blood cells to carry oxygen and aid in various cellular functions.9 Serum ferritin (SF) 
levels are considered normal between 15 and 150 μg/L for women and 200 μg/L for 
men.10 Iron deficient anemia (IDA) is the clinical definition when SF levels are below 12 
μg/L. Low SF levels that do not meet the anemic threshold are classified as iron deficient 
non-anemic (IDNA), which has been identified to have negative effects on fatigue and 
general health.11 Peeling et al. suggested three stages for categorizing iron deficiency.12 
Stage one, iron depletion, is SF levels of <35 µg/L indicating depleted iron stores in the 
spleen, liver, and bone marrow. Stage two, iron deficient erythropoiesis, is SF <20 µg/L 
which diminishes red blood cell production. Stage three, IDA, is SF levels <12 µg/L 
which is when hemoglobin production falls.12   
 
2 
 
Prevalence of ID 
ID is the most prevalent nutritional deficiency in the world and the second most 
prevalent nutrient deficiency in the United States.13,14 ID prevalence is highest among 
women (approximately 9%) and children.12 Premenopausal women have an increased 
risk of ID due to blood loss through the menstrual cycle.1,13 Up to 16% of premenopausal 
women have ID.1,13 Athletes have been found to have higher ID rates than the general 
public. Across 24 sports, it was reported that 31% and 57% of elite male and female 
athletes, respectively were IDNA.15 Kohler et al. also reported 41% of male endurance 
athletes were IDNA. In highly trained female distance runners, the IDNA rate increased 
to 82% even when 75% of the athletes reached their dietary recommendation for iron.5 
Causes of ID 
SF is a measure of stored iron used to test for ID.13 There are a number of reasons 
that endurance athletes’ SF may be low. During the inflammatory response to exercise, 
iron absorption is decreased.16 Inflammation stimulates hepcidin release, a regulator of 
iron entry into circulation, which in turn decreases iron absorption by trapping SF in 
macrophages.16,17 Hepcidin release was found be lower in IDNA endurance athletes 
compared to athletes of normal iron levels.16,18-20 Peeling et al. found a dose response 
where a lower SF level decreased normal hepcidin release during inflammation.16 
Hemolysis, the destruction of red blood cells (RBC), increases the strain on iron stores to 
replace RBCs for oxygen carrying capacity.21 Exercise induced hemolysis occurs due to 
increased intramuscular pressure, mechanical load, and foot strike.21,22 The intramuscular 
pressure may have a greater impact than foot strike as hemolysis rate is more dependent 
on speed and intensity than the running surface.23 Additionally, blood loss due to training 
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can impact SF levels. Hematuria, blood loss through urine, occurs when exercise 
intensity decreases renal blood flow via vasoconstriction.24 Vascular lesions in the upper 
digestive tract of runners may also lead to gastrointestinal bleeding.25 Between the low 
absorption, blood loss, blood damage, and high hemoglobin demand, endurance athletes 
are at an increased risk of developing ID.19,21,23-25 
Health Implications of ID 
Thyroid function, bone integrity, fatigue, and immune function are all impacted 
by SF levels.2-4,26-28 Unexplained fatigue was found to dissipate in women with SF <50 
μg/L following iron supplementation.29 ID associated fatigue may be due to inefficient 
oxygen transport, but thyroid hormones, triiodothyronine (T3) and thyroxine (T4), 
important in metabolism regulation, have been shown to be depressed in IDA and 
IDNA.2,28,30 SF specific affects T3 and T4 are currently unkown.
2 These alterations in 
thyroid hormones are potentially important as they can lead to weight gain, impaired lean 
mass development, affect growth rate, and increase fatigue.28 
Impaired immune function has also been associated with ID. Hospital patients 
with IDA have been found to be more susceptible to infections.31,32 In mice, IDA-related 
infections have been associated with T-cell lymphocyte dysfunction and a decrease in 
interleukin-2 (IL-2).33 Similar immune dysfunction has been seen in ID persons such as a 
decrease in IL-2 (activates white blood cells) and natural killer cell (NK)(rapid response 
to infection) activity along with an increase in interleukin-6 (IL-6)(pro and anti-
inflammatory) and interleukin-10 (IL-10)(anti-inflammatory).3,34,35 A decrease in NK 
activity has been shown in IDNA distance runners compared to distance runners with 
normal iron levels, which may hinder their immune response to infection.36 
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Iron also plays an important role in bone integrity as an enzymatic cofactor for 
collagen synthesis.37 Rat studies have produced most of the findings regarding the effect 
of iron on bone integrity. When rats were fed diets deficient in iron, decreased bone mass, 
bone mineral density (BMD), femur strength, bone formation, and bone mineral content 
have been found, along with an increase in bone fragility.38-41 Decreased BMD has been 
associated with dietary iron, most notably when calcium intake was controlled for, 
proposing that dietary iron impacts BMD independent of calcium.42-45 In addition, in 
women receiving hormone replacement therapy (HRT) a direct relationship between iron 
supplementation and BMD was found.45 These findings suggest iron plays an important 
role in bone health. This is particularly important as Bennell and Crossely found stress 
fractures occurred in 21% of athletes.6 Risk factors of stress fractures include low bone 
density, hormonal factors, caloric restriction, and muscle fatigue, of which iron’s 
relationship to these factors cannot be ignored.46  
Most of the iron research has neglected health outcomes for athletes and instead 
focused on performance. When looking at competitive track and field athletes, 
particularly distance runners, injury rates have been reported from 31% to 57%.6-8 Given 
the high incidence of injury and ID among athletes and the involvement of iron in 
important functions, the impact that ID has on endurance athletes is warranted.  
Need of the Study 
ID has been shown to have negative health and performance implications, thus it 
is important to measure the extent to which the health and training status of distance 
athletes are affected by ID. 
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Purposes of the Study 
The purpose of this study is to investigate the relationship of SF levels and 
training reductions due to injury, illness, and/or fatigue among NCAA Division 1 
collegiate distance runners. 
Research Hypothesis 
Low SF levels will be associated with training reductions due to injury, illness, 
and/or fatigue. 
Operational Definitions 
NCAA Division 1 collegiate distance runners: Athletes competing in a NCAA 
school sponsored cross-country and track and field program.  
Iron levels will be measured by a venous blood draw to measure SF levels: 
1. <12 µg/L clinical anemia (IDA) – decrease in hemoglobin production.12 
2. <20 µg/L iron deficient erythropoiesis (IDNA) - diminished red blood cell 
production.12  
3. <35 µg/L iron depletion (IDNA) - depleted iron stores in the spleen, liver, and 
bone marrow.12 
Significance of the Study 
1. Improved health of athletes is not only beneficial for the well-being of the 
athletes but also for improved performance.   
2. This study will determine whether athletes with lower SF levels experience 
training reductions caused by injury, illness, and/or fatigue than those with 
normal SF levels. 
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CHAPTER TWO: LITERATURE REVIEW 
Iron Deficiency 
Iron deficiency (ID) has been a popular subject of study, with respect to health 
outcomes, due to its high prevalence among the general population, as well as its role in 
oxygen delivery, bone density, immune regulation and thyroid regulation.1-4 ID among 
athletes, particularly endurance athletes, and performance measures have also been 
frequently studied. Endurance adaptation requires consistent, uninterrupted training, due 
to the gradual improvement in mitochondrial density as well as the subsequent decrease 
in mitochondrial density, stroke volume, and performance within the first week of 
exercise cessation.47-49 Injuries, overtraining, fatigue, illness, etc. are all factors that can 
inhibit training and subsequent performance. Hemolysis, hematuria, and gastric lesions 
incurred through endurance training put distance runners at an increased risk for ID.25,50,51 
The importance of iron for these athletes is heightened as the requirements for high 
performance such as maximal oxygen consumption (
2OV
  max), ventilatory threshold, 
and lactate threshold are particularly influenced by ID as iron is essential for oxygen 
transport and is a cofactor in mitochondrial energy production.52 Ironically, while iron 
status and performance have been studied, there is limited research on the impact of ID 
on endurance athletes’ health and training status. The purpose of this review is to 
investigate the training effects of ID with respect to endurance athlete’s health and 
training status. 
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ID Prevalence 
ID is the most prevalent nutritional deficiency in the world and the second most 
prevalent nutrient deficiency in the United States.13,14 ID prevalence is highest among 
women and children.13 Premenopausal women have an increased risk of ID due to blood 
loss during a menstrual cycle.13 In premenopausal women, iron deficiency with anemia 
(IDA, a blood iron concentration of ≤12 μg/L) was identified in 3-5% of the population.1 
Information from the National Health and Nutritional Examination survey from 2003 to 
2006 reported ID rates among 3,742 females aged 12-19 and 20-49 to be 15.6% and 
15.7%, respectively.1 In athletes, the iron deficient non-anemic (IDNA, <35 μg/L) 
prevalence has been found to be higher than the general population.15 Koehler et al. 
analyzed 193 elite athletes across 24 sports for IDNA; 31% of male athletes and 57% of 
female athletes were reported to have IDNA.15 These percentages increased in male 
endurance athletes to 41%, but remained nearly the same in female endurance athletes at 
54%.15 Deuster et al. investigated 51 highly trained female distance runners’ nutritional 
intakes and SF levels and found that although 75% of the athletes consumed an adequate 
amount of dietary iron according to the recommended daily allowance (RDA), 82% were 
IDNA.5 These are very high percentages of IDNA compared to the general population 
and did not appear to be affected by a deficiency of iron within the athlete’s diet. 
Causes of ID 
The increased prevalence of ID in athletes is due to a number of different factors. 
In 2008, Ostojic and Ahmetovic investigated the effect of training volume on ID. 53 
Eighty-four female professional athletes across various sports recorded training hours in 
conjunction with SF measurements.53 Of the sports studied, distance runners were found 
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to have the most training hours per week, at 9.8, and also had the lowest ferritin levels. 
However, IDNA (<30 μg/L, adjusted to represent the degree of IDNA of participants) 
correlated poorly with training volume.53 
Hepcidin 
In 2009, Peeling et al. found a decreased hepcidin response in IDNA (<35 μg/L) 
athletes.19 IDNA may be classified under different SF levels to reflect the degree of 
IDNA of the participants.12,19,53 Hepcidin release is stimulated by inflammation, which in 
turn decreases SF and gut iron absorption.17 Peeling et al. speculated that IDNA may 
decrease hepcidin release, proposing the need for iron overrides the normal response of 
hepcidin to inflammation.19 Auersperger et al. investigated the relationship of iron levels 
and hepcidin in moderately trained females and found that training decreased iron levels 
and hepcidin after 8 weeks.20 A follow-up study by Auersperger et al. had 14 female 
distance runners undergo a 10 week training phase.18 Seven of the distance runners were 
already IDNA (<20 μg/L) and 7 were ≥20 μg/L.18 Following the 10-week training cycle, 
the number of athletes with IDNA (<20 μg/L) increased from 50% to 71%.18 Again 
hepcidin decreased with SF, causing Auersperger et al. to question if iron demand, rather 
than inflammation, influenced hepcidin release.18 Peeling et al. revisited the SF and 
hepcidin relationship with 54 trained male and female endurance athletes.16 The athletes 
were separated into 4 groups according to their SF levels.16 SF levels of the four groups 
was <30 μg/L, 30-50 μg/L, 51-100 μg/L, and >100 μg/L.16 An interval session or long, 
slow distance run was completed followed by a hepcidin measurement.16 Results showed 
a significant dose response of hepcidin, increasing incrementally with SF level pre and 
post exercise.16 Athletes with optimal SF do not appear to require as much iron 
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absorption, thus a greater release in hepcidin occurs.16 None-the-less, hepcidin was still 
released in all groups, decreasing iron absorption in all of the athletes.16   
Hemolysis 
Exercise induced hemolysis (RBC destruction) has been reported among a range 
of exercise conditions including swimming, cycling, resistance training, and 
running.50,51,54 Selby and Eichner found that muscle contraction during exercise 
compressed blood vessels which resulted in hemolysis during non-weight bearing 
activity.54 However, the weight bearing force incurred through running shows the greatest 
degree of hemolysis.50 The damaged RBC’s release hemoglobin (Hb) and the associated 
iron into the plasma where glycoprotein heptoglobin (Hp) “picks up” the remains.55 A 
blood profile with increased free Hb and decreased Hp is common among runners.55 
Hansen et al. found decreased Hp levels in recreational runners, comparable to that seen 
in well-trained distance runners while running on concrete.56 In 1988, Miller et al. 
showed heel-strike force to increase the degree of hemolysis, finding that running 
downhill for an equal amount of time produced greater hemolysis.57 This finding was 
supported by Telford et al. while comparing hemolysis between runners and cyclists.50 
Following a one-hour exercise bout at 75% 
2OV
 max, runners showed a free Hb level up 
to 4 times greater than the cyclists.50 The authors concluded that the major cause of 
hemolysis among runners was heel-strike. However, Peeling et al. had 10 triathletes 
complete two 10 km training sessions, one on pavement and the other on grass.23 
Following the interval sessions, there was no difference between grass and concrete. A 
relationship was found between hemolysis and speed, showing a trend towards greater 
hemolysis during an increased running pace.23 This study points back to intramuscular 
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pressure, generated by increased speeds, to have a greater impact on hemolysis than foot-
strike.23 The degree of hemolysis in runners places an increased strain on iron stores, 
making them more susceptible to ID.50 
Hematuria 
Hematuria (blood in the urine) has also been found to occur with physical activity. 
Gilligan et al. monitored 49 runners in races from 2.6 to 26.2 miles.51 Following the 
strenuous bouts, approximately 25% of the runners were found to have Hb present in 
their urine.51 Blacklock found that movement of the bladder, associated with running, 
hypothesizing that lesions in the interior wall caused hematuria.58 However, McInnis et 
al. found hematuria to be associated with increased exercise intensity utilizing an aerobic 
run, a sprint protocol, aerobic bike, and Wingate protocol.24 Renal blood flow decreased 
proportionally to exercise intensity, with no signs of lesions to the bladder.24 A decrease 
in plasma flow to the kidneys via vasoconstriction appears to be the cause of hematuria.24 
Gastric Lesions 
Gastric lesions causing gastrointestinal bleeding are also an avenue of iron loss 
during exercise. Gaudin et al. performed an endoscopic examination before and after a 
moderately paced long run between 18 and 50km.25 Six of 7 runners had vascular lesions 
in the upper digestive tract ranging between congestion to hemorrhage as result of the 
exercise bout.25 
Sweat Loss 
Iron has also been found in the sweat of cyclists, although sweat may not play a 
significant role. Waller and Haymes measured iron loss through sweat during an exercise 
bout and found nearly two times the amount of iron during the first 30 minutes compared 
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to the second 30 minutes of the session.59 They concluded that the increase in iron loss 
during the first 30 minutes may be due to external contamination of cellular debris.59 A 
review by Zourdos et al. concluded that iron loss through sweat was minor at best.52 
ID and Performance 
Performance testing in regard to ID is a well-researched area. Studies on 
performance and physical fitness parameters have produced mixed results, although most 
studies have found iron supplementation to benefit ID runners.52 In a classic double blind 
study, Rowland et al. took 14 iron deficient runners (<20 µg/L) and supplemented half 
with 975 mg/d of ferrous sulfate with the control group receiving a placebo.60 Both 
groups supplemented for 1 month. The ferrous sulfate group increased their SF from 8.7 
µg/L to 26.6 µg/L while the placebo group fell from 10.6 µg/L to 8.6 µg/L.60 Following 
the supplementation period, 6 of 7 in the treatment group improved their endurance 
treadmill time while the control group’s performance declined.60 Submaximal, maximal
2OV
 , heart rate, or ventilation did not change between groups. Moving into the 2000’s, a 
study took 42 IDNA (≤16 µg/L) women and divided them into ferrous sulfate 
supplementation and placebo groups.61 The treatment group took 100 mg of ferrous 
sulfate for 6 weeks and training took place 5 days/week during the last 4 weeks. Prior to 
testing there was no difference in 15 km time. Both groups improved their 15 km, 
decreased their respiratory exchange ratio, and increased work rate.61 The ferrous sulfate 
group improved their 15km time by 3.4 minutes on average whereas the placebo group 
saw improvements of 1.6 minutes. These improvements were partially attributed to their 
increased SF levels.61 These results were confirmed by Brownlie et al.62 
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In 2007, Peeling et al. injected 100 mg of ferrous sulfate 5 times over the course 
of 10 days into a group of 8 IDNA (<35 µg/L) athletes with a control group receiving a 
placebo injection.12 The average SF level rose from 19 µg/L on day 1 to 65 µg/L on day 
20, and fell to 58 µg/L on day 28 without additional injections.12 Contrary to 
expectations, the results yielded no significant improvement over the control group in any 
parameter including economy, heart rate, blood lactate, submaximal 
2OV
  or 
2OV
 max.12 
These findings go against previous research with oral ferrous sulfate supplementation. 
The study also included a blood test of soluble transferrin receptor (sTfR, a transporter or 
iron into cells) which may be a better indicator of performance improvements regarding 
iron supplementation.12 The authors noted that although intramuscular iron injections 
increased SF levels quicker than oral, sTfR did not change as it had during oral 
supplementation.12 This may be due to the lower overall dose of iron used in the study or 
that the athletes were not deficient enough for sTfR to be compromised.12 
In 2007, Hinton and Sinclair published results from 20 IDNA (≤16 µg/L) 
recreationally trained mean and women with a 6-week study design very similar to their 
own study in 2000.61, 63 The treatment group took oral doses of ferrous sulfate while the 
control group took a placebo. They found a significant improvement in energy efficiency 
during a 
2OV
 max test as well as an increased ventilatory threshold for those who started 
with lower SF levels.63 Similar to Peeling et al. findings with ferrous sulfate injections, 
there was no change in sTfR level which they expected to decrease after iron 
supplementation. 12,63 The contradictory results found between Peeling et al. and Hinton 
and Sinclair may be a result of a higher baseline SF level in the Peeling et al. study. 12,63   
Hinton and Sinclair also noted that sTfR may remain stable or increase in response to 
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muscle growth and erythropoiesis which may diminish its response to iron 
supplementation.63  
In 2014, Della Valle and Haas investigated performance measures in 40 IDNA 
college rowers over 6 weeks of either supplementation with oral SF or placebo.64 Six 
weeks was found to increase blood SF by 3.0 µg/L (p=.07).64 A 4km time trial revealed 
that SF supplementation group significantly improved energetic efficiency and energy 
expenditure whereas the control group did not see an improvement from baseline levels.64 
They also showed a decrease in lactic acid build up in the first half of the time trial and 
were able to clear lactic acid quicker following the time trial.64 
Health Consequences of ID 
With so much research investigating the performance benefits of adequate SF, 
there are relatively few studies investigating the health consequences of ID in athletes. 
There are quite a few health consequences that may occur as a result of ID, although most 
studies investigate the general population. Chronic fatigue, thyroid and resting metabolic 
rate (RMR) alterations, bone integrity, and immunosuppression have been associated 
with ID.2-4 
Thyroid 
Chronic fatigue is often associated with anemia as inefficient oxygen transport 
may be to blame for the fatigue, but IDA has been shown to affect triiodothyronine (T3) 
and thyroxine (T4).
2 T3 and T4, stimulated by thyroid stimulating hormone (TSH), are 
important for their role in metabolism regulation. ID-related thyroid alterations have been 
studied particularly in their role as thermoregulators and their effect on RMR. Dillman et 
al. first showed a decrease in body temperature and T3 in IDA rats.
65 Following this 
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finding, Martinez-Torres et al. found a 10% decrease in T3 among men and women 
during cold water exposure in IDA individuals; however, this decrease was not 
statistically significant.30 They also noted an increase in norepinephrine (NE) and 
2OV
  
during cold water exposure in the IDA participants and theorized that the elevated 
2OV
  
increased the metabolic rate to compensate for the drop in body temperature.30 Beard et 
al. noticed a discrepancy between the groups in the Martinez-Torres at al. study where the 
IDA group had a significantly lower body fat.2, 30 Controlling for body fat, 10 IDA, eight 
iron depleted (IDP, <30 µg/L), and 12 iron sufficient control participants completed a 12 
week iron supplementation protocol of 78 mg of ferrous sulfate daily, again using cold 
water immersion to investigate thyroid hormones.2 Prior to supplementation, the IDA 
group had significantly less T3 and T4 and a lower body temperature, a sign of poor TSH, 
than both the control and IDP groups.2 Following 12 weeks of iron supplementation, the 
IDA group was not able to increase SF to a normal level (3.8 ± 2.4 µg/L to 9.7 ± 5.7 
µg/L) but increased body temperature during cold water immersion, although their body 
temperature was still lower than the control group.2 The IDA group increased their T3 by 
12% after supplementation.2 However, T3  and T4 remained significantly lower in the IDA 
group than both the IDP and control groups following supplementation, a point Beard et 
al. attributed to the inability to correct IDA.2  
A case study published in 2000 followed two female college athletes, a distance 
runner and swimmer, with IDA over 16 weeks of iron supplementation.28 Sixteen weeks 
was sufficient to correct their IDA (5 µg/L to 15 µg/L; 5 µg/L to 20 µg/L), although it 
was not long enough to return SF to normal levels.28 One athlete’s RMR increased, while 
the other’s decreased. The change in RMR may have been a function of T4 as a similar 
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pattern appeared as one athlete’s T4 increased while the other athlete’s decreased. It 
appears that the interaction of iron on thyroid hormones is complex and possibly 
individualized.28 The researchers also noted that iron’s impact on thyroid hormones is 
potentially important, as thyroid decrements can impair the development of lean mass, 
affect growth rate, and increase fatigue.28 
Bone Integrity 
The role of iron in regards to BMD is often overlooked, particularly in an athletic 
setting, where iron’s effect on performance has been heavily researched. Iron contributes 
to bone health as an enzymatic cofactor of the enzyme prolyl hydroxylase for collagen 
synthesis, playing an important function in collagen maturation.37 Most of the 
information of iron’s relationship to BMD comes from rat studies. Medeiros et al. fed rats 
an iron-deficient diet (5–8 mg/kg of iron per day) over 5 weeks after which the rats 
developed increased bone fragility and a decrease in bone mass.41 A similar protocol by 
Katsumata et al. fed rats a diet deficient in iron, according to the AIN-93 purified diets, 
for 4 weeks and the rats showed significantly reduced serum osteocalcin (secreted by 
osteoblasts, increases bone building, bone mineralization and calcium homeostasis).39 
Serum osteocalcin also causes beta cells to release insulin and fat cells to release 
adiponectin (increases sensitivity to insulin) concentration by 56%, which indicates 
inhibited osteoblast (bone cell responsible for bone tissue building) function. Bone 
mineral content, BMD, and femur mechanical strength were also significantly lower in 
the iron-deficient group, suggesting a decrease in bone formation.39 Katsumata et al. set 
up a similar study to clarify previous findings and found significant decrements in bone 
mineral content, BMD, osteoclast surface area(bone cell responsible for bone tissue 
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breakdown), and bone formation rate in rats fed an iron-deficient diet.40 Additionally, 
insulin-like growth factor-1 (promotes growth in children and adults), osteocalcin 
concentrations, and serum 1,25 dihydroxycholecalciferol (calcitriol, promotes dietary 
calcium absorption and calcium release from bone) decreased; suggesting that severe 
iron-deficiency decreases bone formation.40 Díaz-Castro et al. measured bone turnover 
biomarkers among anemic rats fed an iron-deficient diet.38 Among the significantly 
affected measures in the iron-deficient rats, serum procollagen type I N-terminal 
propeptide (PICP) decreased and C-terminal telopeptides of type 1 collagen increased.38 
The decrease in PICP indicates bone mineralization impairment while the C-terminal 
telopeptides of type 1 collagen are degradation products that decrease type 1 collagen 
crosslinking, leading to increased bone fragility and weaker collagen fibers.38 
In humans, Harris et al. found dietary iron to be associated with greater BMD in a 
cross sectional study of 242 postmenopausal women.44 Iron had already been associated 
with high BMD in two other human studies, however, in this particular study calcium 
was controlled for and iron was still associated with a greater BMD.42-44 Harris et al. 
concluded that dietary iron may be more important in bone mineralization than 
previously thought.44 In 2005, the effect of iron supplementation on bone health in 
postmenopausal women again showed iron’s importance in bone health.45 Two-hundred 
and twenty-eight women receiving hormone replacement therapy (HRT) supplemented 
with calcium and iron and the effects on the participants bone health were monitored over 
1 year. The novel finding was the positive association of SF and BMD.45 A direct relation 
of iron supplementation with positive bone mineral density during HRT was also 
demonstrated.45 Only one study has been conducted on premenopausal women. One-
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hundred and sixty-five women were divided into two ID groups (≤30 μg/L) and an iron 
sufficient group (>30 μg/L) over 16 weeks.4 The ID groups either supplemented with iron 
or iron in addition to vitamin-D fortified skim milk.4 Toxqui et al. found an inverse 
relationship between N-terminal telopeptide (NTx), which reflects bone reabsorption, and 
SF. 4 The ID groups showed increased bone reabsorption, which is the first time iron 
biomarkers have been related to bone turnover markers in premenopausal women.4 Thus, 
both bone reabsorption and remodeling were related to ID.4 
Immune Suppression 
Patients with IDA have been found to be more susceptible to infections.31,32 
Latunde-Dada and Young associated IDA-related infections with T-cell lymphocyte 
dysfunction and a decrease in Interleukin-2 (IL-2) causing immune system impairment 
among mice.33 Sipahi et al. found a decrease in IL-2 among ID children.34 Following iron 
supplementation, IL-2 increased in the children to normal values.34 In 20 adult patients 
with IDA, Bergman et al. found IL-2 to be decreased as well as an increase in IL-6, IL-
10, and tumor necrosis factor-alpha (TNF-α).3 Considering the important role of IL-2, 
stimulating natural killer cells (NK) and T-cell lymphocyte proliferation, IDA may 
contribute to an increased susceptibility to infections.3 In those with IDNA (12-30 μg/L), 
Chandra showed untrained individuals had a lower NK cell activity than participants with 
normal SF levels.27,31,35  Additionally, Chandra explains that iron is needed by neutrophils 
(which respond and protect against infection) and lymphocytes (made up of T cells, B 
cells, and NK cells, important for immune response) for proper function.35 In patients 
with ID, aged or degenerated neutrophils are common, although how iron affects this is 
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still unkown.35 Lymphocytes appear to require iron for proliferation and function.66 These 
immune alterations illuminate the importance of iron’s role in immune function.35,66 
Braun et al. investigated NK cell activity and iron status in female collegiate swimmers.26 
Ten swimmers and 9 sedentary participants had their SF and NK cell activity measured 
late into the swim season. Both groups were IDNA, with the swimmers SF at 20.38 ± 
2.73 μg/L and sedentary participants at 16.79 ± 3.51 μg/L.26 Results showed that the 
swimmers had higher NK cell activity; however, both groups were considered to be 
IDNA so the baseline set by the sedentary participants may not be reflective of NK 
activity among those with normal SF levels.26 A double blind study investigated female 
distance runners iron status and immune function during two weeks of intensified 
training.67 Twenty-three well trained distance runners completed 2 weeks of normal 
training to distinguish the typical training volume of each individual.67 SF and NK cell 
activity were measured before and after a 2 week increase in training volume, a 40% 
increase the first week and an additional 40% increase the second week, followed by 8 
weeks of recovery training.67 Runners with SF below 35 μg/L were considered to have 
low iron scores.67 Following the two week increase in training volume, the low iron 
group had significantly decreased NK cells, which is associated with lower NK cell 
activity.67 This finding suggests there is some link between immune function and iron 
status.67 Following the 8 week recovery phase, in which the low iron group supplemented 
the SF scores above 35 μg/L, NK cell activity was still depressed.67 This suggests that the 
immune system may require longer periods of normal iron stores or that other factors 
may be involved to alter immune function.67 
 
19 
 
Injury Rates of Distance Runners 
Numerous studies have investigated the prevalence and associations of running 
and injuries. The injury rate among distance runners have been found to be between 19.4-
79.3% for lower extremity injuries, and up to 92.4% when all injuries are included.68 
However, competitive distance runners have reported injury rates at 43%, 31%, and 
57%.6-8 Stress fractures have been found in 21% of track and field athletes.6 
Unfortunately, those studies did not find particular causes for the injuries. The majority 
of studies looking at injury rates among runners are in recreational runners that are older 
than the typical college athletes.68 Limited and contradictory evidence associated running 
injuries with age, gender, height, weight, leg length differences, competition, and running 
pace.68 An increased training volume has been found to be a significant predictor of 
injury in runners, particularly above 64 kilometers/week.69,70 However, two studies with 
marathon runners showed a protective effect of knee and foot injuries with increased 
training volume.71,72 Previous injury may be the most significant predictor of injury as 4 
studies have found an association between injury rate and injury history.69,70,72,73 These 
findings are inconclusive relating injury to a common cause, particularly among young, 
college athletes. With the high incidence of injury and ID, along with the important role 
iron plays, further investigation into ID is warranted. 
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CHAPTER THREE: METHODS 
Participants 
Data from 47 Division 1 distance runners (30 females, 17 males), aged 18-24 
years, were analyzed in this cross sectional study. Data were compiled from September 
through December 2014 and again in September through December 2015. This study was 
approved by the Institutional Review Board and no experimental intervention took place. 
Data Set 
The data set included weekly mileage, SF levels, injury type, degree of injury, 
fatigue symptoms, and degree of fatigue symptoms. These data sets were of particular 
interest as it has a number of important parameters regarding endurance athletes’ health 
and success with injuries, weekly mileage, and SF levels.  
SF was used to assess iron levels as it is the most sensitive test to measure stored 
iron.13 Each athlete’s SF levels were measured via venous blood samples by the student 
health clinic and analyzed with a Beckman Dxi 800 immunoassay system in the first 
week of September and again the second week of December. Participants were instructed 
not to supplement with iron 24 hours prior to testing.  
Injuries and fatigue symptoms were self-reported by athletes to the team’s athletic 
trainers, who diagnosed and treated injuries throughout the training seasons. Athletic 
trainers referred athletes to a medical doctor for diagnosis if a further diagnosis was 
warranted. The athletic trainers completed weekly reports on athlete’s injury status. 
Injuries were divided into 2 types: bone or tissue injuries. Injury location, type, and 
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severity were recorded. Fatigue symptoms were reported as chronic fatigue or the 
particular sickness an athlete had, such as mononucleosis, influenza, etc. Severity of 
injury and fatigue symptoms were measured on 5 levels, from 0 to 4 increasing with 
severity (Table 1).  
Table 1. Severity of Injury, Illness, and Fatigue as Ranked by Athletic 
Trainers 
Classification Severity Training Load Effect 
Level 0 No Injury Continue at normal training load 
Level 1 Minor Injury No reduction in training load 
Level 2 As Tolerated Continue normal training load if tolerable 
Level 3 Limited Decrease in training load 
Level 4 Out No practice sessions or cross training 
 
During times of injury or fatigue symptoms, athletes may have participated in 
rehabilitation exercises and/or cross training sessions depending upon the athletic 
trainers’ and coaches’ discretion. If an injury was believed to be a tissue injury, but later 
found to be a bone injury, previous weekly injury reports were edited to reflect the new 
diagnosis. Mileage was self-reported by athletes on a weekly basis, recorded by the 
coaches, and used to cross check injury status. 
Procedure 
Participants supplemented with liquid ferrous sulfate elixir (220 mg/5 ml, 
Pharmatech, Livonia, MI). A gradual increase in ferrous sulfate elixir occurred over 4 
weeks according to the United State Olympic Committee (USOC) recommendations, 
shown in Table 2. Based on the initial SF measure, athletes were instructed to follow the 
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weekly recommendations until they reached their designated SF level, at which point 
they stayed on that regimen until the next testing date. 
Table 2. USOC Iron Supplementation Protocol 
 Serum Ferritin Level Orange Juice/Vitamin C Ferritin Sulfate Elixir 
Week 1 Females < 40 μg/L, 
Males < 50 μg/L 
8 oz. OJ + 500 mg Vit. C 5 ml x 2 per day 
Week 2  8 oz. OJ + 500 mg Vit. C 10 ml x 2 per day 
Week 3 Females < 30 μg/L, 
Males < 40 μg/L 
8 oz. OJ + 500 mg Vit. C 15 ml x 2 per day 
Week 4 Females < 20 μg/L, 
Males < 30 μg/L 
8 oz. OJ + 500 mg Vit. C 15 ml x 3 per day 
 
Females below 20 μg/L and males below 30 μg/L followed dosage through week 
4 and continued with that dosage. Females below 30 μg/L and males below 40 μg/L 
followed dosage through week 3 and continued with that dosage. Females below 40 μg/L 
and males below 50 μg/L followed the week 1 dosage. Athletes with a SF ≥ 40 μg/L and 
≥ 50 μg/L, for females and males respectively, supplemented according to week 1 of the 
USOC iron supplementation protocol to maintain their SF. Following the SF measure in 
December, athletes adjusted their intake accordingly. Along with the iron 
supplementation guidelines, participants were given additional informational resources 
explaining iron supplementation in regards to calcium, which blocks absorption, and 
vitamin C, which increases absorption.74 
Data Analysis 
SF was analyzed on a continuous scale and was grouped into iron depleted (≤35 
μg/L) and normal (>35 μg/L) groups for data analysis. Following supplementation and 
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retesting, the athletes were separated into two groups based on their SF. If an athlete was 
IDNA during their pre or post SF, they were placed in the IDNA group. If an athlete was 
not IDNA during their pre and post SF, then they were placed in the normal iron group 
(N). Training reduction was categorized as no reduction in training, which corresponded 
with injury levels 0, 1, and 2 according to the athletic trainer assessment. Level 3 was 
classified as partial training reduction (training continued but at a reduced volume) and 
level 4 was classified as complete training reduction (no training). For data analysis, 
levels 0, 1, and 2 were combined to level 0 reflecting no reduction in training volume. 
Level 3 (partial training reduction) was classified at level 1 and level 4 (complete training 
reduction) as level 2. Weekly mileage and injury/fatigue symptom severity were 
compared to ensure accurate classification of training reduction. 
Descriptive statistics were conducted for age, gender, injury incidence, injury 
type, injury severity, SF level, and weekly mileage. A generalized linear model analysis 
was used to determine the association between Pre and post SF levels, mileage, and 
gender as predictors of a reduction in training volume. Using the 2 groups following the 
post SF test, a chi-squared was used to analyze the difference in training reduction among 
the groups. SPSS (Version 22, IBM Corp. Armonk, NY) was used for all statistical 
analyses and statistical significance was set at ≤0.05. 
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CHAPTER FOUR: RESULTS 
Data were collected on 17 male and 30 female NCAA Division I collegiate 
distance runners between the ages of 18 and 24 ( x  ± sd = 20.00 ± 1.69 years) with a 
mean school year of 2.34 ± 1.23. SF measures and mileage are presented in Table 3. The 
average pre SF was 37.5 ± 19.0 μg/L and increased to 53.8 ± 24.2 μg/L. Women’s pre 
and post SF, 31.3 ± 14.1 μg/L and 48.4 ± 22.4  μg/L, respectively, were significantly 
lower than the men’s SF (Pre: 49.0 ± 21.5 μg/L, Post: 63.3 ± 24.9 μg/L) (Pre: p=0.001, 
Post: p=0.04). SF improved by an average of 15.8 ± 22.2 μg/L. There was a wide 
variation in the SF changes across the study population, with one athlete’s SF decreased 
by 19 μg/L while another’s increased by 114 μg/L. Those who supplemented with a 
higher dose of ferrous sulfate elixir led to a greater SF increase, although there was no 
significant difference between the lowest (88 mg of elemental iron) and middle (246 mg) 
supplement groups. However the highest (396 mg) supplement group was significantly 
different from the lowest (88 mg) supplement group (p=0.002) (see Table 4). Those on 
the highest supplementation (396 mg) improved SF by 34.2 ± 31.6 μg/L, the second 
highest (264 mg) improved SF by 16.7 ± 18.1 μg/L and the least amount of 
supplementation (88 mg) improved by 7.7 ± 14.4 μg/L. Training volume averaged 60.7 ± 
17.4 miles/week (53.5 ± 16.3 miles/week for women, 73.5 ± 10.9 miles/week for men) 
with a minimum of 17 miles/week and a maximum of 92 miles/week. 
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Table 3. Pre and Post SF Values, SF Change, and Training Volume of the 
Distance Runners Measured During the Cross Country Season 
 N Mean Min Max Std. Deviation 
Pre SF (μg/L) 47 37.5 10 86 19.0 
     Male 17 49.0 13 86 21.5 
     Female 30 31.1 10 57 14.1 
Post SF (μg/L) 47 53.8 15 131 24.2 
     Male 17 63.3 32 109 24.9 
     Female 30 48.4 15 131 22.4 
SF change (μg/L) 47 15.8 -19 114 22.2 
Volume (miles/wk) 47 60.7 17 92 17.4 
 
Table 4. SF’s Response to Supplementation Dose 
 
Of the 47 athletes whose data were analyzed, 11 (23%) experienced a complete 
reduction in training volume, 16 (34%) experienced a partial reduction in training 
volume, and 20 (43%) did not experience a reduction in training due to injury, illness, or 
fatigue (Table 5). Twenty-three athletes had normal SF levels above 35 μg/L and 20 
maintained normal SF levels, while three fell into IDNA, at the post SF test. Twenty-four 
athletes were IDNA at the pre SF test. Fifteen were able to correct their IDNA while nine 
remained IDNA at the post SF test.  Eighteen of the 30 female athletes and nine of the 19 
Iron Supplement N Change in SF (μg/L) Std. Deviation 
Group 1 (88 mg) 24 7.7 14.4 
Group 2 (264 mg) 13 16.7 18.1 
Group 3 (396 mg) 10 34.2 31.6 
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male athletes experienced a reduction in training. The chi-square test performed to 
examine training reductions between the N group and IDNA group found IDNA to be 
significantly associated with training reduction, X2 = 7.19, N = 47, p = 0.027.  Training 
reductions are shown in Table 5 and group information is shown in Table 6. In the N 
group, seven of the 20 (35%) athletes experienced a reduction in training due to injury, 
illness, or fatigue, while the IDNA group had 20 of 27 athletes who experienced a 
reduction in training.  
Table 5. Training Reductions Experienced by the N and IDNA Groups 
 N No Training 
Reduction 
Training 
Reduction 
Partial 
Reduction 
Full 
Reduction 
N group (>35 μg/L) 20 13 (65.0%) 7 (35.0%) 4 (20.0%) 3 (15.0%) 
IDNA group (≤35 μg/L) 27 7 (25.9%) 20 (74.0%) 12 (44.4%) 8 (29.6%) 
 
Table 6. SF and Training Volume Differences Between N and IDNA Groups 
 Sex 
(M, F) 
Pre SF 
(μg/L) 
Post SF 
(μg/L) 
SF Change 
(μg/L) 
Training Volume 
(miles/wk) 
N group (>35 μg/L) 11, 9 55.1 ± 13.9 68.1 ± 19.4 11.9 ± 15.1 70.4 ± 11.2 
IDNA group (≤35 μg/L) 6, 21 24.5 ± 9.2 43.5 ± 22.1 18.7 ± 26.2 53.6 ± 17.9 
 
A multinomial generalized linear model was run to predict how reductions in 
training were effected by training volume, gender, pre SF, and post SF (Table 7). 
Training volume, Pre SF, and Post SF were statistically significant (p<0.05), while 
gender was not. As pre SF decreases, there is a 4.3 % increase in the likelihood of 
experiencing training reductions due to injury, given all other variables are held constant. 
As post SF increases, there is a 3.3% increase in the likelihood of experiencing a training 
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reduction due to injury. As training volume decreases there is a 5.8% increase in the 
likelihood of experiencing a training reduction due to injury. 
Table 7. Parameter Estimates for the Linear Model of Training Reduction 
Associated with Pre SF, Post SF, and Training Volume. 
 Exp(B) B Std. Error df Sig. 
Pre SF 1.043 0.042 0.0212 1 0.049 
Post SF 
Training Volume 
0.967 
1.058 
-0.033 
0.057 
0.0169 
0.0229 
1 
1 
0.05 
0.013 
 
  
28 
 
CHAPTER FIVE: DISCUSSION 
The purpose of this study was to investigate the relationship between SF and 
reductions in training due to injury, illness, or fatigue. The hypothesis was that SF would 
be associated with training reductions. The IDNA group was found to have a significantly 
higher rate of training reductions (74%) compared to the N group (35%). Pre SF and 
training volumes were negatively correlated with training reductions, suggesting that a 
low SF and low training volume were associated with reductions in training. Post SF was 
positively correlated, suggesting that a relationship between training reductions and a 
higher post SF, although this may be due to those with low SF dramatically improving 
their SF. 
Women’s average SF was significantly lower than men’s SF with 70% of women 
in the IDNA group while only 35% of men were in the IDNA group. The IDNA 
prevalence among women was expected as women are at a higher risk of ID due to 
menstrual blood loss.1,13 However, the generalized linear model did not find any 
significant associations between sex and training reductions. On average, SF increased by 
15.8 ± 22.2 μg/L, which was enough to correct IDNA in 62.5% of the IDNA group. This 
suggests that the supplementation and dietary recommendations were adequate for some 
athletes to improve SF levels in 14 weeks. Previous research has found similar 
improvements in SF, between 13 μg/L and 20 μg/L, with supplementation amounts of 
100-200 mg of elemental iron over 4-16 weeks, with most improvement occurring in the 
first two weeks.60,75-77 A more aggressive oral supplementation may be effective, as the 
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group of athletes that supplemented with the greatest amount of ferrous sulfate (396 mg) 
experienced an improvement in SF of 34.2 μg/L in 14 weeks. Changes in Hb were only 
found in two studies and did not occur until 8 weeks and 16 weeks from the start of 
supplementation.77,78 There was a wide variation in SF change, with a maximum increase 
of 114 μg/L and a decrease of 19 μg/L, suggesting that some athletes may respond well to 
increased iron intake. Eight (17%) of the athletes experienced a decrease in SF, which 
may reflect the increased strain on SF caused by training such as hemolysis, hepcidin 
release, and hematuria.19,23,24 Additionally, some of the athletes may not have been 
compliant with the supplement guidelines or were non-responders, although the literature 
does not make any mention of non-responders. However, adherence to and the 
effectiveness of the supplementation protocol is unknown as supplementation and dietary 
intake compliance were not monitored. The variation in SF improvement is partially due 
to the graduated supplementation protocol, but may also be affected by supplementation 
practices and individual variation. Due to variation in SF improvement and for adjusting 
supplementation dosage, athletes should have SF retested regularly and iron intake 
monitored to observe supplementation effectiveness for the individual. 
The IDNA group experienced more than twice as many partial and complete 
training reductions (74%) as the N group (35%). Training reduction occurred due to a 
variety of injuries (stress fractures, muscle strains, etc.), illness (mononucleosis, upper 
respiratory tract infection, flu, etc.), and fatigue symptoms (elevated resting HR, general 
perceived fatigue, etc.). Of the 27 IDNA athletes, 74% experienced a reduction in 
training due to injury, illness, and/or fatigue while 35% of the N group experienced a 
training reduction. This suggests that the health consequences of ID, such as 
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compromised bone integrity, immune suppression, and fatigue, may contribute to training 
reductions in IDNA athletes.2-4,26,28,31,32,44 As pre SF decreases, a 4.3% increase in the 
likelihood of a training reduction was found. Although training reductions were expected 
at a higher rate in the IDNA group, a linear correlation was not expected, as iron 
depletion occurs at <35 μg/L.12 However, the cutoff of <35 μg/L for detrimental effects 
may not explain the whole situation, as unexplained fatigue in women with ≤50 μg/L was 
found to improve with iron supplementation.29 Thyroid hormones, bone biomarkers, 
immune function, and fatigue were not directly measured; therefore the training 
reductions cannot be directly related to those issues potentially related to low SF. 
This is the first study to find an association between SF and training reductions 
caused by injury, illness, and/or fatigue. Previous studies that have investigated running 
injuries explored age, gender, height, weight, leg length differences, competition, and 
running pace found no definite cause.68 In trained distance runners, a few studies have 
found previous injury to be the only repeated finding with significance.69,70,72,73 The 
variation in injury type and individual athletes presents difficulty in finding a specific 
cause for running injuries. However, there are a number of reasons ID may effect the 
health and training of athletes. ID has been found to compromise bone integrity, which is 
particularly alarming when stress fractures were found in 21% of track and field 
athletes.4,7,40,44 Immune suppression, particularly a decrease in NK cells, has also been 
seen in ID female distance runners undergoing an increase in training volume. Flynn et 
al. suggested that it may take normal iron stores a while to regain normal immune 
function as NK cells remained below normal levels 8 weeks following the intervention, 
although how long this make take is unknown.67 Decreased thyroid hormones have also 
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been associated with an increase in training load among female rowers. Baylor and 
Hackney found 10 of 17 women’s TSH and T3 decreased following intense training, 
while it has also been shown that ID affects thyroid hormones.2, 79 The various ways in 
which ID and IDNA effect bone health, the immune system, and thyroid function, as well 
as the alarmingly high rate of IDNA among these male and female athletes (35% and 
70% respectively) suggests that nutritional deficiencies may play an important role in 
maintaining health and training. Although bone, immune system, and thyroid biomarkers 
were not measured in the current study, a number of the injuries, illnesses, and fatigue 
symptoms have the potential to be a symptom of ID. This is not to say that all injuries are 
caused by ID, but that ID may create an adverse environment for an athlete to overcome 
the stress of training. Maintaining training volume may also have a performance benefit 
as well. Assuming that the training stimulus and rest are appropriate, athletes that are able 
to maintain their training load should continue to improve whereas an injured, sick, or 
tired athlete will miss out on the training adaptation until they are healthy enough for 
such activity. 
Interestingly, high post SF levels were associated with a reduction in training. 
This finding may be due to a number of factors regarding the timing of the post SF 
measurement. Athletes were re-tested in December, which may have occurred well after 
the reduction in training occurred. Therefore, SF at the time of injury, illness, or fatigue 
symptoms was not known. At the same time, athletes had decreased their training load by 
this time, which may reduce the stress on SF. Additionally, the athletes with low initial 
SF levels had a higher supplementation dose, causing a five-fold and two-fold increase in 
SF levels above the lowest and middle supplementation groups (see Table 4), possibly 
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elevating their post SF levels, although the post SF of the IDNA (43.5 μg/L) was not 
higher than the post SF of the N group (68.1 μg/L). However, four of the individuals who 
were IDNA during the pre SF measurement were among the highest during the post SF 
measurement, particularly the highest post SF value of 131 μg/L, which started at 17 
μg/L. Therefore, this finding may be reflective of the greater SF supplementation, and 
subsequent greater improvement in SF, in the athletes with more pronounced ID. 
Furthermore, training volume was negatively associated with training reduction 
due to injury, suggesting that athletes who trained at a higher volume were injured less 
often. In recreational runners, increased training volume above 64 kilometers/week was 
found to be a significant predictor of injury.69,70 However, in recreational marathon 
runners, training volume has been found to be protective of injury.71,72 This association 
may only show that runners who are healthy are able to run more miles. Weeks of 
reduced training due to injury, illness, or fatigue were not included when calculating 
average weekly training volume in an attempt to eliminate the effect of the training 
reduction on weekly training volume averages.  
The use of pre-existing data limited this study and therefore SF was not measured 
at the time of injury. Additionally, potential ID detriments such as thyroid hormone 
regulation, bone biomarkers, and immune function were not investigated. Although 
prescribed, the athlete’s supplementation and the dietary recommendations to increase 
iron intake were not monitored for compliance and do not allow a true measure of the 
effect of the supplementation protocol. Furthermore, there may be some association that 
athletes who take great care to remain healthy also follow the supplementary and dietary 
recommendation more closely. 
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Conclusions 
IDNA and low pre SF levels were associated with training reductions due to 
injury, illness, and fatigue. This finding does not suggest that every injury, illness, and/or 
fatigue is cause by ID, but that ID may lower an athlete’s resistance to particular injuries 
or illnesses that may require a reduction in training. Surprisingly, less weekly volume and 
high post SF levels were associated with training reductions, although the post SF 
measurement did not occur at the time of injury. Previous research on athlete’s iron levels 
has primarily focused on performance.60-62 However, research on the health and training 
status of ID athletes is lacking, as only a couple studies have investigated the effects of 
ID in athletes.28,67 SF measurement and iron supplementation, along with dietary 
instructions to increase iron intake, may decrease the need for injury, illness, and fatigue-
related training reductions among collegiate distance runners. Coaches and trainers 
should have SF levels measured prior to and following a season to monitor SF levels and 
see how well an athlete responds to iron supplementation. Future research should 
investigate ID’s effect on other groups of athletes, measuring SF at the time of injury, and 
monitoring corrected IDNA’s effect on training. Further investigations into particular 
biomarkers of bone, immune, and thyroid function in ID athletes may prove beneficial for 
the health and training of athletes.   
Practical Application 
Coaches should have athlete’s SF tested every 3-4 months to see if they are IDNA 
(<35 μg/L). Even if athletes are near 35 μg/L, supplementation may be beneficial due to 
the finding that unexplained fatigue in women with a SF of <50 μg/L improved following 
supplementation.29 A good time to test SF would be during preseason or prior to a 
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competitive season to allow SF time to improve. Prior to testing, athletes should avoid 
iron supplementation and meals high in iron content. SF testing on an empty stomach is 
recommended. If an athlete’s SF is low, they should supplement and make dietary 
changes to increase iron intake. The USOC supplementation protocol (see Table 2), as 
well as dietary recommendations, were effective in maintaining or improving 83% of the 
athlete’s SF in this study. Ferrous sulfate elixir is a liquid form of iron (available over the 
counter at local pharmacies) which should be taken with orange juice and a 500 mg 
vitamin C pill to increase absorption.80 Athletes should avoid consuming calcium near 
supplementation as it blocks the absorption of iron.80 Supplementing 30 minutes prior to 
a meal may be an effective strategy to avoid calcium intake near supplementation. 
Ferrous sulfate elixir often has an unpleasant taste and may cause teeth discoloration. An 
effective method of ingesting ferrous sulfate elixir is to mix the supplementation amount 
with 1-2 ounces of orange juice and swallow with minimal teeth contact, followed by 8 
ounces of orange juice and a vitamin c pill. Brushing immediately after may help to avoid 
teeth discoloration. Iron supplementation may initially cause gastric distress and black 
stools. Athletes should be retested every 3-4 months to avoid toxicity levels (1,000 μg/L), 
to remain within the upper limit of the normal SF range (women: 150 μg/L, men: 200 
μg/L) and to make individual adjustments to supplementation amount.81 
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